Profile
Claude Perreault is the founder of Epitopea Ltd.
(founded in 2021).
Dr. Perreault is also the founder of SpecificiT Pharma, Inc.
Claude Perreault active positions
| Companies | Position | Start |
|---|---|---|
SpecificiT Pharma, Inc.
 SpecificiT Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services SpecificiT Pharma, Inc. develops personalized cancer immunotherapies. The company is headquartered in Westmount, Canada. | Founder | - |
Former positions of Claude Perreault
| Companies | Position | End |
|---|---|---|
Epitopea Ltd.
 Epitopea Ltd. Miscellaneous Commercial ServicesCommercial Services Epitopea Ltd. is a British transatlantic biotechnology company that develops immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication. The company is based in Cambridge, UK. The company has an extensive proprietary library of cryptigen™ tsas that will drive the development of transformational off the shelf cancer immunotherapies. Epitopea was founded in 2021 by Jonathan David Moore, Claude Perreault, and Pierre Thibault. Jonathan David Moore has been the CEO since 2021. | Founder | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
SpecificiT Pharma, Inc.
SpecificiT Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services SpecificiT Pharma, Inc. develops personalized cancer immunotherapies. The company is headquartered in Westmount, Canada. | Commercial Services |
Epitopea Ltd.
Epitopea Ltd. Miscellaneous Commercial ServicesCommercial Services Epitopea Ltd. is a British transatlantic biotechnology company that develops immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication. The company is based in Cambridge, UK. The company has an extensive proprietary library of cryptigen™ tsas that will drive the development of transformational off the shelf cancer immunotherapies. Epitopea was founded in 2021 by Jonathan David Moore, Claude Perreault, and Pierre Thibault. Jonathan David Moore has been the CEO since 2021. | Commercial Services |
- Stock Market
- Insiders
- Claude Perreault
